Topamax (topiramate) – Ongoing EU review of potential risk of NDD
18/10/2022
Medicines for human use
Direct healthcare professional communication (DHPC)
Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero